A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children

NCT ID: NCT04750902

Last Updated: 2024-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

2000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-21

Study Completion Date

2024-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to assess the safety and to evaluate the anti-caries efficacy of COL101 (arginine) non-fluoride dentifrices compared to a 0.24% sodium fluoride dentifrice in 10-14 year-old children over a one year period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dental Caries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.24% Sodium Fluoride Dentifrice

Toothpaste

Group Type ACTIVE_COMPARATOR

0.24% Sodium Fluoride Dentifrice

Intervention Type DRUG

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

1.5% Arginine Dentifrice

Toothpaste

Group Type EXPERIMENTAL

1.5% Arginine Dentifrice

Intervention Type DRUG

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

4.0% Arginine Dentifrice

Toothpaste

Group Type EXPERIMENTAL

4.0% Arginine Dentifrice

Intervention Type DRUG

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

8.0% Arginine Dentifrice

Toothpaste

Group Type EXPERIMENTAL

8.0% Arginine Dentifrice

Intervention Type DRUG

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.24% Sodium Fluoride Dentifrice

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Intervention Type DRUG

1.5% Arginine Dentifrice

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Intervention Type DRUG

4.0% Arginine Dentifrice

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Intervention Type DRUG

8.0% Arginine Dentifrice

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects meeting all criteria below will be included in the study:

1. Subject assent and parental/guardian informed consent for voluntary participation.
2. Willingness and ability to use the assigned products according to instructions, availability for all appointments and likelihood of completing the clinical trial.
3. Children ages 10-14 years at baseline.
4. Presence of permanent second molars or evidence of at least one permanent second molar erupting as indicated by cuspal break through the mucosa.
5. Good general health as evidenced by a review of the medical history.
6. Subjects who, at study entry, have present two or more active caries lesions (ICDAS scores of 2 or greater) in permanent teeth and previous caries experience (DMFT \>1), D= Decayed is defined as ICDAS scores of 3 or greater

Exclusion Criteria

* Subjects presenting any of the criteria below will be excluded from the study:

1. Presence of fixed or removable prosthetic appliance or orthodontic treatment involving more than four permanent teeth.
2. Use of medication that could increase the risk of developing dental caries, i.e.

medications that reduce saliva flow and those with high sugar content.
3. Long-term antibiotic therapy.
4. Children with a confirmed diagnosis of cognitive and/or motor impairment.
5. Severe malocclusion.
6. Subjects who, at study entry, have present severe caries (ICDAS 5 or 6) on five or more permanent teeth.
7. Evidence of moderate to severe periodontal disease.
8. Participation in any other clinical study within the 30 days preceding the start of the clinical study.
9. Known history of allergies or other adverse reactions to arginine, or oral care products, or their ingredients.
10. Self-reported history of being currently pregnant, intending to become pregnant during the trial period or breast-feeding.
Minimum Eligible Age

10 Years

Maximum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Colgate Palmolive

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria E Ryan, DDS PhD

Role: STUDY_DIRECTOR

Colgate-Palmolive Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Loma Linda University School of Dentistry

Loma Linda, California, United States

Site Status

University of Florida College of Dentistry

Gainesville, Florida, United States

Site Status

Indiana University School of Dentistry

Indianapolis, Indiana, United States

Site Status

Tufts University School of Dental Medicine

Boston, Massachusetts, United States

Site Status

The Forsyth Institute

Boston, Massachusetts, United States

Site Status

University at Buffalo School of Dental Medicine

Buffalo, New York, United States

Site Status

University of Pennsylvania School of Dental Medicine

Philadelphia, Pennsylvania, United States

Site Status

UT Health San Antonio School of Dentistry

San Antonio, Texas, United States

Site Status

University of Puerto Rico School of Dental Medicine

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRO-2020-CAR-ARG-ED

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Bleeding-Model Clinical Study
NCT05916508 COMPLETED NA
Dentinal Hypersensitivity Reduction
NCT06244290 COMPLETED PHASE3